trending Market Intelligence /marketintelligence/en/news-insights/trending/IixG8pbhGyPvs9gjsmoaQw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Approvals for Sarepta Therapeutics, Amarin; designations for Dermira, CSL

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Approvals for Sarepta Therapeutics, Amarin; designations for Dermira, CSL

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Dec. 13.

Approvals

* Sarepta Therapeutics Inc.'s Vyondys 53 injection for Duchenne muscular dystrophy, or DMD. The drug was granted accelerated approval after an initial rejection by the U.S. regulator in August.

* Amarin Corp. PLC's Vascepa to reduce risk of cardiovascular events in patients with triglyceride levels of 150 milligrams per deciliter or higher, who also have established cardiovascular disease or diabetes plus at least two other cardiovascular risk factors.

* PerkinElmer Inc.'s GSP Neonatal Creatine Kinase-MM kit to test for DMD in newborns.

* Tandem Diabetes Care Inc.'s Control-IQ Technology for automated insulin delivery, which allows automatic adjustments of the insulin dose based on blood glucose readings and a history of insulin delivery.

* Cochlear Ltd.'s Osia 2 System ear implant that uses wireless technology.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: AP Photo

Fast track

* Dermira Inc.'s lebrikizumab for atopic dermatitis.

* Equillium Inc.'s itolizumab for kidney inflammation in lupus patients.

* VistaGen Therapeutics Inc.'s nasal spray PH94B for social anxiety disorder.

Other designations

* Orphan drug, for CSL Ltd.'s Hizentra as a maintenance therapy to prevent the return of chronic inflammatory demyelinating polyneuropathy in certain adult patients.

* Rare pediatric disease designation, for Y-mAbs Therapeutics Inc.'s GD2-GD3 Vaccine for children with neuroblastoma.